The field has moved fast. Not long ago longevity was treated as a curiosity; now Longevity's a real investment category, on track to reach $67B by 2035. That shift is the thing worth paying attention to. The good companies aren't selling immortality. They're going after healthspan, treating aging as a root cause, and measuring themselves against clinical results.

Stéphane Molère is the founder and president of Private Equity Valley, a private investment and wealth structuring platform within the Éthique & Patrimoine group. Longevity is not about living longer—it is about protecting judgment, capital, and legacy over time. Stéphane Molère explains why. To Win Long Term, First Avoid Losing On Longevity, Risk, and Capital.

L Catterton, the private equity fund backed by LVMH and Groupe Arnault, has invested up to US$5 million in WTHN, the New York-based brand that modernises Traditional Chinese Medicine (TCM) through a clean, design-led luxury model.